On December 10th, the "Top 50 Shanghai Startups with the Most Investment Potential in 2024" list was officially announced at the "Bund Finance·Shanghai International Equity Investment Forum." Shanghai Escugen Biotechnology Co., Ltd. (hereinafter referred to as "Escugen") was honored to be included on the list, marking another recognition of Escugen's scientific and technological innovation capabilities and investment potential by the industry.
The selection of the "Top 50 Shanghai Startups with the Most Investment Potential in 2024" was organized under the guidance of the Shanghai Municipal Commission of Economy and Informatization, jointly conducted by the Shanghai SME Office, the Shanghai SME Service Center, the Shanghai Investment Promotion Service Center, and three industry associations including the Shanghai International Equity Association. The selection process was launched in mid-October. Over a hundred companies were evaluated through expert judging panels, online popularity voting by the public, and due diligence by professional credit investigation agencies, ultimately resulting in the final list. This is the ninth consecutive year that Shanghai has organized the "Top 50 Startups with the Most Investment Potential" selection. Companies on the list are included in the "Shanghai Key Incubation Startup Database," and nearly a hundred venture capital member of the three equity investment associations in Shanghai will focus on these companies to connect with financial capital.
"Startups on the list are expected to accelerate their integration into Shanghai's modern industrial system of '(2+2)+(3+6)+(4+5)', with scientific and technological innovation as the core driving force, to become the 'vanguard' of New Quality Productivity and the 'main force' of High-quality Development," said Rong Zhiqin, Deputy Director and Senior Inspector of the Shanghai Municipal Commission of Economy and Informatization. He also called on financial institutions to increase their support for high-quality small and medium-sized enterprises, make good use of the platform built by the government for industrial capital and high-quality startups, and ensure smooth financing channels to safeguard the High-quality Development of SMEs.
Dr. Zhou Qing, Co-founder and CEO of Escugen, said, "We are very honored to receive this recognition. We are grateful to the Commission of Economy and Informatization, industry associations, expert judges, and investors for their recognition of Escugen. This is the result of the hard work of all Escugen employees. We will continue to focus on scientific and technological innovation, take the mission of benefiting global patients, and strive to become the 'vanguard' of New Quality Productivity and the 'main force' of High-quality Development."
About Escugen Biotechnology
Escugen is a clinical-stage biotechnology company located in Shanghai, China, focusing on the development of innovative ADC (Antibody-Drug Conjugate) drugs. Currently, Escugen's most advanced Trop-2 ADC pipeline, ESG401, has entered Phase III clinical trials. Escugen's next-generation linker-payload technology platform, EZWi-Fit®, offers significant competitive advantages in terms of safety, efficacy, anti-multiple drug resistance, and pharmacokinetic characteristics. Leveraging this platform technology, Escugen is rapidly expanding its ADC product pipeline targeting new or validated targets. The company has also successfully licensed this platform technology to several domestic and international biotechnology companies to empower their innovative ADC projects.
